1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Varicose Veins Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Varicose Veins Treatment Market, by January
8.1.1. Endovenous Ablation
8.1.1.1. Market Revenue and Forecast
8.1.2. Endovenous Laser Therapy
8.1.2.1. Market Revenue and Forecast
8.1.3. Radiofrequency Ablation
8.1.3.1. Market Revenue and Forecast
8.1.4. Injection Sclerotherapy
8.1.4.1. Market Revenue and Forecast
8.1.5. Surgical Ligation & Stripping
8.1.5.1. Market Revenue and Forecast
9.1. Varicose Veins Treatment Market, by End-Use
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast
9.1.2. Ambulatory Surgical Centers
9.1.2.1. Market Revenue and Forecast
9.1.3. Specialty Clinics
9.1.3.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by January
10.1.2. Market Revenue and Forecast, by End-Use
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by January
10.1.3.2. Market Revenue and Forecast, by End-Use
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by January
10.1.4.2. Market Revenue and Forecast, by End-Use
10.2. Europe
10.2.1. Market Revenue and Forecast, by January
10.2.2. Market Revenue and Forecast, by End-Use
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by January
10.2.3.2. Market Revenue and Forecast, by End-Use
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by January
10.2.4.2. Market Revenue and Forecast, by End-Use
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by January
10.2.5.2. Market Revenue and Forecast, by End-Use
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by January
10.2.6.2. Market Revenue and Forecast, by End-Use
10.3. APAC
10.3.1. Market Revenue and Forecast, by January
10.3.2. Market Revenue and Forecast, by End-Use
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by January
10.3.3.2. Market Revenue and Forecast, by End-Use
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by January
10.3.4.2. Market Revenue and Forecast, by End-Use
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by January
10.3.5.2. Market Revenue and Forecast, by End-Use
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by January
10.3.6.2. Market Revenue and Forecast, by End-Use
10.4. MEA
10.4.1. Market Revenue and Forecast, by January
10.4.2. Market Revenue and Forecast, by End-Use
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by January
10.4.3.2. Market Revenue and Forecast, by End-Use
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by January
10.4.4.2. Market Revenue and Forecast, by End-Use
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by January
10.4.5.2. Market Revenue and Forecast, by End-Use
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by January
10.4.6.2. Market Revenue and Forecast, by End-Use
10.5. Latin America
10.5.1. Market Revenue and Forecast, by January
10.5.2. Market Revenue and Forecast, by End-Use
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by January
10.5.3.2. Market Revenue and Forecast, by End-Use
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by January
10.5.4.2. Market Revenue and Forecast, by End-Use
11.1. Medtronic
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Lumenis Be Ltd.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. AngioDynamics
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Sciton
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Quanta System
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Intros Medical Laser GmbH
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Alma lasers
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Dornier MedTech
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Theraclion
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Abbott
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
